Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00429273 · ClinicalTrials.gov registry record · Phase 4
Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder
A Phase 4 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 212
- Enrollment target
NCT00429273: Completed Phase 4 study, sponsored by University of California, Los Angeles.
NCT00429273 is a Phase 4 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 212 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00429273, a Phase 4 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 212 participants
- Enrollment target
Study Summary
This study will evaluate the effectiveness of a single drug versus a combination of drugs in treating attention deficit hyperactivity disorder in children.
Primary Outcome
The primary clinical efficacy variable for treatment was the ADHD-RS-IV (Attention-Deficit/Hyperactivity Disorder Rating Scale) Total Score and two sub-scales (Inattentive and Hyperactive-Impulsive ). The rating scale has 18 questions with answer options: None (0), Mild (1), Moderate (2) and Severe (3). Min 0; max 3. Scores are obtained by summing each item; The higher the score, the worse the outcome. Total score range: 0-54 Total Inattentive score range: 0-27 Total Hyperactive/Impulsive sco
Interventions
- DRUG Guanfacine
- DRUG Methylphenidate (MPH)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2007-01 |
| Est. Completion | 2011-07 |
| Phase | Phase 4 |
What the finished NCT00429273 record still lists
NCT00429273 is an interventional study that assigns participants to a tested intervention. The registered 212 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 2 interventions - of which Guanfacine is the first listed.
NCT00429273 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00429273 about?
NCT00429273 is a clinical study titled "Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder". This study will evaluate the effectiveness of a single drug versus a combination of drugs in treating attention deficit hyperactivity disorder in children.
What is the current status of trial NCT00429273?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 212 participants. The study started on 2007-01. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00429273?
The interventions under investigation include: Guanfacine (DRUG), Methylphenidate (MPH) (DRUG).
Who is sponsoring clinical trial NCT00429273?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00429273's enrollment target sits among peer trials
212 396th of 2000 higher than 1,603 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
- NCT06456593 · 212 participants · Phase 2
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia